Shares of Claritev (NYSE:CTEV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $33.6667.
CTEV has been the subject of several research analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th. UBS Group reaffirmed a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th. Wells Fargo & Company dropped their price objective on Claritev from $30.00 to $22.00 and set an “equal weight” rating for the company in a research note on Thursday, March 19th. Piper Sandler set a $61.00 price objective on Claritev in a research note on Wednesday, June 3rd. Finally, Canaccord Genuity Group initiated coverage on Claritev in a research note on Friday, May 29th. They issued a “buy” rating and a $32.00 price objective for the company.
Check Out Our Latest Stock Analysis on Claritev
Claritev Price Performance
Institutional Investors Weigh In On Claritev
Large investors have recently bought and sold shares of the stock. H&F Corporate Investors VIII Ltd. acquired a new stake in Claritev during the 3rd quarter valued at $285,988,000. Oak Hill Advisors LP acquired a new stake in Claritev during the 3rd quarter valued at $4,871,000. Topline Capital Management LLC acquired a new stake in Claritev during the 3rd quarter valued at $10,711,000. Citigroup Inc. acquired a new stake in Claritev during the 3rd quarter valued at $2,025,000. Finally, Beach Point Capital Management LP grew its holdings in Claritev by 77.4% during the 4th quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock valued at $32,276,000 after buying an additional 329,424 shares during the last quarter. Institutional investors and hedge funds own 87.15% of the company’s stock.
About Claritev
Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.
See Also
- Five stocks we like better than Claritev
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.
